ASO Visual Abstract: Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion as First- or Second-Line Therapy for Metastatic Uveal Melanoma

Ann Surg Oncol. 2025 Jan;32(1):501-502. doi: 10.1245/s10434-024-16307-4.

Helana Ghali^#¹, Michelle M Dugan^#², Shaliz Aflatooni¹, Aleena Boby¹, Danielle K DePalo^{2

3}, José Laborde⁴, Junsung Choi^{5

6}, Altan F Ahmed^{5

6}, Jonathan S Zager^{7

8}

¹ University of South Florida Morsani College of Medicine, Tampa, FL, USA.
² Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
³ Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA, USA.
⁴ Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
⁵ Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA.
⁶ Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
⁷ Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. [email protected].
⁸ Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. [email protected].

^# Contributed equally.

No abstract available